Shanghai Pharmaceuticals (HKG:2607) is proposing to take part in the establishment of the Biomedical M&A Fund as a limited partner alongside various other parties and contribute 1 billion yuan to the fund, a Monday bourse filing said.
The pharmaceutical company's capital commitment represents nearly 20% of the total commitment of 5.01 billion yuan by all the partners.
The fund will be managed by executive partner Shanghai Shangshi Capital Management, which is a unit of Shanghai Shangshi (Group), the controlling shareholder of Shanghai Pharmaceuticals.
The fund has an initial investment period of four years, with an initial exit period also comprising four years.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。